SHAREHOLDER ALERT: WeissLaw LLP Reminds DUC, CIT, and CBLI Shareholders About Its Ongoing Investigations

NEW YORK,, Dec. 9, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

Duff & Phelps Utility and Corporate Bond Trust Inc. (NYSE: DUC)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Duff & Phelps Utility and Corporate Bond Trust Inc. (NYSE: DUC) in connection with the company's proposed merger with DNP Select Income Fund Inc. ("DNP").  Under the terms of the merger agreement, DUC will merge into DNP, with DNP as the surviving company of the merger.  The combined fund will retain DNP's name and will continue to trade on the New York Stock Exchange under DNP's ticker symbol.  If you own DUC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/duc/ 

CIT Group Inc. (NASDAQ: CIT)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CIT Group Inc. (NASDAQ: CIT) in connection with the proposed acquisition of the company by First Citizens BancShares, Inc. ("FCNCA").  Under the terms of the agreement, CIT shareholders will receive 0.0620 shares of FCNCA common stock for each share of CIT common stock that they own, representing implied per-share merger consideration of $37.76 based upon FCNCA's December 8, 2020 closing price of $609.01.  If you own CIT shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/cit/   

Cleveland BioLabs, Inc. (NASDAQ: CBLI) 

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cleveland BioLabs, Inc. (NASDAQ: CBLI) in connection with the proposed merger of the company with Cytocom, Inc.  Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one newly-combined entity that will continue to trade publicly.  If you own CBLI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:   https://weisslawllp.com/cbli/

SOURCE WeissLaw LLP

Related Links

http://weisslawllp.com